Stephen Hillis, MD
Family Medicine · Tacoma, WANPI 1356314967
Payments from drug & device makers
Across 158 payments — averaging $47.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rivanna Medical, Inc$5K
- AbbVie$383
- Takeda Pharmaceuticals U.S.A., Inc.$319
- Amgen$315
- AstraZeneca$266
- Mayne Pharma Commercial LLC$240
- plus $974 from 21 others
What the payments were for
- Consulting fees$5,02567%
- Food & beverage$2,47733%
- Education$200%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rivanna Medical, Inc | 1 | $5,025 |
| AbbVie(2 entities) | 27 | $383 |
| Takeda Pharmaceuticals U.S.A., Inc. | 28 | $319 |
| Amgen | 9 | $315 |
| AstraZeneca | 14 | $266 |
| Mayne Pharma Commercial LLC | 35 | $240 |
| Amarin Pharma, Inc. | 8 | $167 |
| Lilly USA, LLC | 7 | $152 |
| Ironshore Pharmaceuticals Inc. | 3 | $133 |
| Johnson & Johnson | 3 | $76 |
| Boehringer Ingelheim | 3 | $70 |
| Daiichi Sankyo Inc. | 2 | $43 |
| Biohaven Pharmaceuticals, Inc. | 2 | $41 |
| Merck | 2 | $35 |
| Bausch Health US, LLC | 2 | $34 |
| Medtronic | 1 | $27 |
| Greer Laboratories, Inc. | 1 | $24 |
| Genentech USA, Inc. | 1 | $22 |
| IBSA Pharma Inc. | 1 | $20 |
| Circassia Inc. | 1 | $19 |
| Novo Nordisk | 1 | $19 |
| Seqirus USA Inc | 1 | $18 |
| Shire North American Group Inc | 1 | $18 |
| Currax Pharmaceuticals LLC | 1 | $15 |
| Pfizer | 1 | $15 |
| Adlon Therapeutics L.p. | 1 | $14 |
| Jazz Pharmaceuticals Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,522 in reported general payments places this provider in the 95th percentile of 2,275 family medicine providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 32 | $32,882 |
| OzempicSemaglutide | 17 | $20,530 |
| TrulicityDulaglutide | 13 | $10,569 |
| FarxigaDapagliflozin Propanediol | 12 | $7,987 |
| SynthroidLevothyroxine Sodium | 80 | $4,501 |
| Rosuvastatin Calcium | 250 | $2,531 |
| Ezetimibe | 63 | $1,268 |
| Lisinopril | 125 | $1,037 |
| Metformin Hcl ErMetformin Hcl | 43 | $784 |
| Atorvastatin Calcium | 107 | $769 |
| Amlodipine Besylate | 112 | $743 |
| Omeprazole | 40 | $713 |
| Telmisartan | 34 | $694 |
| Olmesartan Medoxomil | 43 | $508 |
| Ramipril | 45 | $422 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $70 | $32,88232 claims |
| Novo NordiskOzempic | $19 | $20,53017 claims |
| Lilly USA, LLCTrulicity | $152 | $10,56913 claims |
| AstraZenecaFarxiga | $266 | $7,98712 claims |
| AbbVieSynthroid | $383 | $4,50180 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,275 family medicine providers in Washington.
Other family medicine in Tacoma
- James RoscettiTacoma$184K
- Marse McNaughtonTacoma$24K
- Benjamin DyTacoma$15K
- Anton GraschWenatchee$5.3M
- Gaylon KippBellevue$4.8M
- Steven KasterWenatchee$4M
- Angela EakinSpokane$3M
- Jonathan StabenCheney$2.5M
- Emily ZaragozaSeattle$1.9M
- Brad FrandsenPort Orchard$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.